There are new questions about the future of U.S. transportation funding after the election. Experts are eyeing a shift in priorities, with local transit measures seeing success in unexpected places and tensions rising over partisan divides. While federal investments in infrastructure have sparked broad support, the future of transportation policy — at both the federal and local levels — remains uncertain, influenced by everything from climate goals to regional politics. Senior Staff Writers ( *) and ( *) join the podcast for a special post-election episode of to discuss the prospects for transit during a time of political transition. Here are the top-five takeaways from this episode: to stories referenced in the episode: Governing Government TechnologyWhy Is Astronics Corporation (ATRO) An Undervalued Aerospace Stock to Buy According to Hedge Funds?
Prepare for uncertain, shock-prone future, Bank of Canada head tells B.C. crowdThe UK has been battered with , ice, strong winds and rain - in what forecasters are calling a "multi-hazard event" as this morning. Large swathes of the north have already been blanketed in snow, with as much as 16 inches set to fall amid rare amber weather warnings issued by the for snow and ice. Disruption and delays have , leaving Brits due to travel from Newcastle, Leeds and Bradford stranded on flights for as long as three hours. has also been forced to ground 36 domestic and European flights to and from today, including two round-trips to Glasgow, Manchester and Nice. It comes as snow is expected as far south as the Welsh valleys, particularly around Aberdare, but the heaviest will be later in the morning across Cumbria and Lancashire. Elsewhere, the heaviest of the rain is feared across the Isle of Man, Dumfries and Galloway and the Scottish Borders. Brits have even been urged to stock up on essentials ahead of the storm as the country also braces for 70mph winds and heavy rain. Many have been warned they should expect power cuts – with some rural communities expected to become completely cut off over the coming days. British Gas customers were reportedly advised to stockpile three days’ worth of food and water if the weather disrupts travel and power. The energy provider also urged Brits to keep phone chargers, torches and batteries nearby. National Highways issued a "severe weather alert" for snow in Yorkshire and north-east England - with "blizzard conditions" set to arrive and up to five hours of heavy snow expected to "accumulate quickly at all levels". It said: "As the snow turns to rain, a rapid thaw is expected to set in as temperatures quickly rise with localised flooding possible." Met Office spokesman Oli Claydon said Storm Bert was a "multi-hazard event". He said: "We're looking at strong winds, some high snowfall accumulation, heavy rain, all in various different parts of the UK. So it's quite a complex weather set-up for the weekend. Generally speaking, it's a very unsettled weekend of weather ahead."Banque Cantonale Vaudoise bought a new position in Abercrombie & Fitch Co. ( NYSE:ANF – Free Report ) during the third quarter, HoldingsChannel reports. The firm bought 1,881 shares of the apparel retailer’s stock, valued at approximately $263,000. Several other hedge funds have also bought and sold shares of ANF. Matrix Trust Co bought a new position in shares of Abercrombie & Fitch in the second quarter valued at $35,000. Farther Finance Advisors LLC lifted its position in Abercrombie & Fitch by 81.5% in the 3rd quarter. Farther Finance Advisors LLC now owns 274 shares of the apparel retailer’s stock valued at $38,000 after acquiring an additional 123 shares in the last quarter. Quarry LP boosted its stake in Abercrombie & Fitch by 156.0% during the 2nd quarter. Quarry LP now owns 279 shares of the apparel retailer’s stock valued at $50,000 after purchasing an additional 170 shares during the last quarter. CWM LLC increased its holdings in Abercrombie & Fitch by 242.6% during the 2nd quarter. CWM LLC now owns 531 shares of the apparel retailer’s stock worth $94,000 after purchasing an additional 376 shares in the last quarter. Finally, GAMMA Investing LLC raised its stake in shares of Abercrombie & Fitch by 39.2% in the third quarter. GAMMA Investing LLC now owns 788 shares of the apparel retailer’s stock worth $110,000 after purchasing an additional 222 shares during the last quarter. Wall Street Analysts Forecast Growth Several research analysts recently issued reports on ANF shares. Morgan Stanley cut their target price on Abercrombie & Fitch from $155.00 to $147.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 29th. UBS Group upped their target price on shares of Abercrombie & Fitch from $165.00 to $170.00 and gave the stock a “neutral” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. raised their price target on shares of Abercrombie & Fitch from $194.00 to $195.00 and gave the company an “overweight” rating in a research report on Friday, October 4th. Citigroup raised shares of Abercrombie & Fitch from a “neutral” rating to a “buy” rating and set a $190.00 price objective for the company in a research report on Friday, August 30th. Finally, Jefferies Financial Group lifted their target price on shares of Abercrombie & Fitch from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, September 4th. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat, Abercrombie & Fitch has a consensus rating of “Moderate Buy” and an average target price of $177.43. Insider Activity In other news, EVP Samir Desai sold 19,041 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $131.36, for a total value of $2,501,225.76. Following the sale, the executive vice president now owns 27,985 shares of the company’s stock, valued at $3,676,109.60. The trade was a 40.49 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Also, CFO Scott D. Lipesky sold 9,000 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $146.80, for a total transaction of $1,321,200.00. Following the completion of the transaction, the chief financial officer now directly owns 106,455 shares of the company’s stock, valued at approximately $15,627,594. This trade represents a 7.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders have sold 31,541 shares of company stock valued at $4,310,256 in the last 90 days. Insiders own 2.58% of the company’s stock. Abercrombie & Fitch Stock Performance Shares of ANF stock opened at $152.00 on Friday. The firm has a market cap of $7.76 billion, a price-to-earnings ratio of 16.10 and a beta of 1.50. Abercrombie & Fitch Co. has a 52 week low of $72.13 and a 52 week high of $196.99. The firm’s 50-day simple moving average is $142.72 and its two-hundred day simple moving average is $152.96. Abercrombie & Fitch ( NYSE:ANF – Get Free Report ) last posted its quarterly earnings results on Wednesday, August 28th. The apparel retailer reported $2.50 EPS for the quarter, topping analysts’ consensus estimates of $2.14 by $0.36. Abercrombie & Fitch had a net margin of 10.76% and a return on equity of 47.35%. The company had revenue of $1.13 billion for the quarter, compared to analysts’ expectations of $1.09 billion. Analysts forecast that Abercrombie & Fitch Co. will post 10.35 earnings per share for the current year. Abercrombie & Fitch Company Profile ( Free Report ) Abercrombie & Fitch Co, through its subsidiaries, operates as an omnichannel retailer in the United States, Europe, the Middle East, Asia, the Asia-Pacific, Canada, and internationally. The company offers an assortment of apparel, personal care products, and accessories for men, women, and kids under the Abercrombie & Fitch, abercrombie kids, Hollister, and Gilly Hicks brands. Read More Want to see what other hedge funds are holding ANF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abercrombie & Fitch Co. ( NYSE:ANF – Free Report ). Receive News & Ratings for Abercrombie & Fitch Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abercrombie & Fitch and related companies with MarketBeat.com's FREE daily email newsletter .
Published 10:57 pm Thursday, December 12, 2024 by Steve Flowers Our legendary governor of the 1940s and 1950s was the giant, cartoonish, character James E. “Big Jim” Folsom. Ole Big Jim ran against the big businesses of Birmingham — big banks, utilities and U.S. Steel — and labeled them the “Big Mules.” He campaigned on the back of a flatbed truck in every hamlet in the state. He would dance and sing with his band, the Strawberry Pickers, and rail against the Big Mules of Birmingham and the Big Planters of the Black Belt. George Wallace came onto the scene in the 1960s. Wallace was a protégé of Big Jim Folsom. Wallace, like Big Jim, Huey Long of Louisiana and other southern political demagogues knew you had to find a boogeyman to run against. Wallace had an easy target. His boogeyman was the race issue. He became the most ardent racist segregationist in the south. However, that issue played out when Blacks were given the right to vote in 1965, and quickly constituted 25 percent of the electorate. Wallace had to find a new boogeyman to run against, so like his mentor, Big Jim, Wallace went after the last Big Mule standing — Alabama Power Company. Wallace was the ultimate demagogue, but history reveals that what is good for Alabama Power is good for Alabama. While nobody likes paying power bills, most of us fail to consider what we get for our money. We want to see the lights come on when we flip the switch and Alabama Power does a better job at making that happen than just about anybody. Email newsletter signup Three years ago, a historic winter blast of cold air on Christmas Eve made the lights go out in Georgia. They also went out in Mississippi, Tennessee and the Tennessee Valley of Alabama, as rolling blackouts spread across the South. However, the lights stayed on in Alabama Power territory. Yet, when the lights do go out in the middle of the storm, you can rest assured a lineman from Alabama Power will weather the storm, leaving his home and family to get the power back on for your home and family. Alabama Power does more than just keep the lights on. It has been the driving force behind economic development in Alabama for an entire century. Today, while industries are abandoning plans for investments in other southern states because they cannot get a reliable supply of electricity, business is booming in Alabama Power territory. This is because the leadership of Alabama Power has refused to buckle to left-wing advocates that suggest we run steel mills and factories off solar panels and windmills. A group calling itself Conservatives for Clean Energy has hired shady political operatives to attack Alabama Power and promote so-called “clean energy.” Anytime a pro-solar and pro-windmill group puts the word “conservative” in their name, you can bet there is nothing conservative about them. Fortunately, for the past decade, our Public Service Commission, which regulates utilities, has had strong leadership and the backbone to stand up to the left-wing forces that would have us sitting in the dark, freezing and paying higher bills. The president of the PSC, Twinkle Cavanaugh, is as smart and tough as they come. Along with her fellow commissioners, she has held the line on regulations that keep the lights on, the jobs coming, and the cost of electricity at about the national average. To the contrary, Texas deregulated utilities a few years ago and left power suppliers on their own to meet the demands of America’s second-biggest state. Windmills and solar panels went up everywhere and utilities cut their maintenance budgets to the bone. Then, in the winter of 2021, the sun went down, the windmills literally froze up, and people started dying. Even as late as this past August, Texas faced rolling blackouts because the utilities could not meet demand. One reason Alabama is not Texas is because our Public Service Commission demanded that Alabama Power put Alabama families, businesses and industries ahead of the left-wing environmentalist agenda. It is the PSC’s job to hold the power company and all the businesses they regulate accountable, and they do. The commission has proven it will hold the power company’s feet to the fire. For example, the PSC has not granted a rate increase since 2021, and the commission monitors the cost of fuel and other expenses on a monthly basis. The PSC has done an excellent job requiring the power company to cut the fat without sacrificing the muscle needed to care for Alabama families and create more jobs. Some people will keep taking shots at Alabama Power because they are an obvious Big Mule boogeyman — but it has always been true, if you’ve got a heavy load to pull you need a big mule. Steve Flowers served 16 years in the state legislature. He may be reached at steve@steveflowers.us. (Column) Robert F. Kennedy Jr.: Will he make America healthy again? (Dave says) Your income is the key (Column) Alabama vs. Auburn, a house divided (Column) The Trump Triumph
None
On Sunday morning, Ole Miss fans held onto a sliver of hope that they could somehow sneak into the College Football Playoffs. However, it wasn't meant to be, and at the end of the season, the rankings placed them at No. 14. Javascript is required for you to be able to read premium content. Thanks for the feedback.
US President-elect Donald Trump filed a brief Friday urging the Supreme Court to pause a law that would ban TikTok the day before his January 20 inauguration if it is not sold by its Chinese owner ByteDance. "In light of the novelty and difficulty of this case, the court should consider staying the statutory deadline to grant more breathing space to address these issues," Trump's legal team wrote, to give him "the opportunity to pursue a political resolution." US President-elect Donald Trump filed a brief Friday urging the Supreme Court to pause a law that would ban TikTok the day before his January 20 inauguration if it is not sold by its Chinese owner ByteDance. "In light of the novelty and difficulty of this case, the court should consider staying the statutory deadline to grant more breathing space to address these issues," Trump's legal team wrote, to give him "the opportunity to pursue a political resolution." Trump was fiercely opposed to TikTok during his 2017-21 first term, and tried in vain to ban the video app on national security grounds. The Republican voiced concerns -- echoed by political rivals -- that the Chinese government might tap into US TikTok users' data or manipulate what they see on the platform. US officials had also voiced alarm over the popularity of the video-sharing app with young people, alleging that its parent company is subservient to Beijing and that the app is used to spread propaganda, claims denied by the company and the Chinese government. Trump called for a US company to buy TikTok, with the government sharing in the sale price, and his successor Joe Biden went one stage further -- signing a law to ban the app for the same reasons. Trump has now, however, reversed course. "Now (that) I'm thinking about it, I'm for TikTok, because you need competition," he recently told Bloomberg. "If you don't have TikTok, you have Facebook and Instagram -- and that's, you know, that's Zuckerberg." Facebook, founded by Mark Zuckerberg and part of his Meta tech empire, was among the social media networks that banned Trump after attacks by his supporters on the US Capitol on January 6, 2021. The ban was driven by concerns that he would use the platform to promote more violence. Those bans on major social media platforms were later lifted. In the brief filed on Friday, Trump's lawyer made it clear the president-elect did not take a position on the legal merits of the current case. "President Trump takes no position on the underlying merits of this dispute," John Sauer wrote in the amicus curiae -- or "friend of the court" -- brief. "Instead, he respectfully requests that the court consider staying the act's deadline for divestment of January 19, 2025, while it considers the merits of this case, thus permitting President Trump's incoming Administration the opportunity to pursue a political resolution of the questions at issue in the case." (Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)Upstart Holdings chief legal officer sells $446,284 in stock
Cloud AI Solutions Market Poised for Explosive Growth, Reaching $254.6 Billion by 2031 | TMRLawmakers say ballot redesign bill will see changes before vote
The days of checking one's stocks in the newspaper and calling up their stockbroker to make trades are long over. Today, people get faster, more reliable, and more accurate information in the form of mobile apps. Even trading stocks has become easy with most brokerage apps available on the market today. Thus, it is easier than ever not only to get into investing but also to keep an eye on your investments and interact with them as needed right from your smartphone. The App Store is, well, the best and currently only place to start looking for investment apps for iOS. There are a ton of them on there that range from brokerage apps like Robinhood to side hustle investment apps like Acorns and everything between. There are also apps that are dedicated to showing you news, charts, up-to-the-second stock prices, and some even integrate things like cryptocurrency into the mix. No matter the kind of investment tracking you want, the App Store has an app for that. However, it can be sometimes difficult to figure out where to begin. Here are some of the best investment apps on the App Store based on user reviews. Keep in mind, though, that while user reviews are a good jumping off point, a considerable number of them can be fake depending on the app. The first place you should always start is with your brokerage's app. Nearly all of them have a mobile app these days from big dogs like Fidelity, Charles Schwab, Vanguard, E*Trade, and others to younger upstarts like Robinhood, WeBull, and Public. These apps house an enormous amount of information, including up-to-date stock prices and watchlists, and often include things like news and other important information. Since these apps actually house your portfolio, they are the de facto method to track it. The other big benefit to getting in with your brokerage account is that you can actually trade there. The rest of the investment apps on this list will let you view your portfolio, but only your brokerage app will let you physically trade stocks. You can also set up things like stop-loss sales and other advanced trading moves. Even if you intend on using a separate app to track everything, you should still become familiar with what your brokerage account offers. It just makes sense. Brokerage apps can often offer other types of features. For instance, Fidelity can link most bank accounts and act as a financial tracker as well as a brokerage app, giving you two-in-one functionality if you feel like going through the effort. Some, like Fidelity and Charles Schwab, also let you open bank accounts in the event you want everything under one roof. Chase also lets you trade stocks on top of managing your personal finances. Apple's Stocks app is good enough to give it a try before going off to find a third-party app. The Apple Stocks app has the benefit of being completely free, which is harder to find than you might think in this space. In addition to the stock market, Apple Stocks also lets users track mutual funds, multiple indexes, ETFs, and currency exchange rates. For the most part, Apple Stocks is best for news and keeping track of ticker prices. It aggregates news from various sources and is powered by Apple News, giving users plenty to read about stocks on their watchlists. It's also available on most Apple devices, including iPad, Apple Watch , Mac, and the Apple Vision Pro . Since the app syncs with your Apple account, there is minimal work for people who want their stock news on multiple devices as you'll be ready to fire up Apple Stocks as soon as you set up your device. In terms of ease of use, Apple Stocks wins out, as it only takes a few minutes to get used to. On the downside, it's not quite as powerful as other investment apps on the platform. You can keep track of your investments through watchlists but can't track them directly. In addition, other apps have better analytical tools and more chart views to give serious traders more data to work with. This is a nice secondary app to use in addition to a brokerage app. Delta Investment Tracker is one of several stock analysis and news apps featured on the list. Its main goal is similar to Apple Stocks, where you can keep track of various stock market activities and news directly through the app. Unlike Apple Stocks, you can log in through your brokerage account to track your investments directly, so you can get all of the information in one spot and only use your brokerage app to physically make trades. In addition to stock market information, Delta also does cryptocurrencies, NFTs, forex, and commodities. For the most part, Delta is at its best when it's being used for research. It includes various stock metrics along with graphs, news, and widgets that you can use to track specific items on the home screen or lock screen. There is also the option to log in with your crypto wallet to keep track of your crypto investments, making Delta an excellent all-in-one app for both things. It might take a day or two to get used to all the information being shown, but the basic functions are simple enough to get started immediately. Delta also has a premium subscription service for $7.99 per month or $99.99 per year. The subscription unlocks more portfolio analysis tools along with a "Why is it moving?" feature that will drop bits of news whenever a stock is soaring or plunging so you can see what's going on. Having officially launched in 2014, Investing.com's iOS app is one of the oldest and most popular on the platform. It's about as typical as an non-brokerage investment app gets on any platform. Its main claim to fame is its ability to create watchlists, view news about various stocks, and keep track of various things. You can port your portfolio in to keep track of it directly, which makes Investing.com a good one-stop-shop for this sort of data. On top of news aggregation and stock statistics, you'll also get access to some decent extra features, such as alerts when stocks hit certain price points and an earnings calendar so you can see when the company's you follow show off their earnings reports. Such tools help investors keep up on the very latest and plan ahead for potentially big events. Like many, it also follows things like commodities, ETFs, and more. Also like others, Investing.com has a subscription model for additional features. There are two tiers: One is $15.99 per month and the other is $39.99 per month. Getting the subscription removes ads from the app and adds some additional features like access to more metrics and data, company health scores, and a stock picker function to give you ideas of where to invest. According to Investing.com, their picks outperform the S&P most of the time, so it's not a bad way to go if you're a beginner and need some ideas on where to start. StockTwits is an interesting investment app. For many years, it operated as an investment tracker app. Users could keep track of their investments, check out stock prices, and read the news about various stocks. However, in 2022, the company started allowing the trading of stocks on its platform. It integrates with Robinhood, Fidelity, and several other brokerages and you actually trade through them while using the StockTwits app to keep track of the investments. The ability to trade is built right into the regular user interface, making it somewhat unusual in this space. StockTwits' biggest claim to fame is its social network style. It shows the usual information but encourages users to post their thoughts about various stocks to give investors additional perspectives outside of what's on the news. It's not the only app that allows commentary on stocks. Yahoo Finance does this too. However, StockTwits leans into it a lot more, making it one of the main attractions of going with the app over competitors. The app also has a subscription if you want to go that route. A simple $85 per year removes ads from the platform, allowing you to browse the app and website ad-free. Stepping up to the $229.50 per year subscription adds more features, including social sentiment data collected from the app, advanced searching, more metrics, and the ability to make posts on the site that are up to 10,000 characters long, much longer than free members. Reddit isn't an investment app, but a lot of modern investors use it. There are myriad subreddits on the platform that deal with stock trading, including Stocks, StockTrading, and PennyStocks, among others. Many of those communities cater to varying experience levels as well, so if you want to read a detailed report, there are subreddits for that, and if you want to learn how to trade, there are subreddits for that as well. In terms of social features, all but potentially StockTwits fall short of what you get on Reddit. In addition to the aforementioned subreddits, you can also follow companies on Reddit to see upcoming news, rumors, and other stuff that might impact stock prices that may not make it to Bloomberg or Yahoo. There are also meme stock subreddits, like Wall Street Bets, where you can find various information about various stocks. There is a warning, though, that there are many people making suggestions and much like gambling, the house usually wins, so we recommend doing your own research. Overall, this is a good tertiary app for investors. You can keep track of things that might get filtered out of other apps and publications. You can't keep track of stock prices or anything, but it never hurts to look at raw social sentiment data, and that's something Reddit allows you to do exceptionally well once you know what to look for. Take any advice in terms of trading with a grain of salt, as anyone can post on Reddit, no matter wrong or right. TipRanks is another above-average investment app that people seem to like on iOS. It ticks all of the usual boxes. You can keep track of your investments, check out the stock market at large, and keep tabs on the news about the companies you want to track. Like similar apps like Delta or Investing.com, it aims to be an all-in-one app to track investments and get information. In addition, the app tracks the top 100 cryptocurrencies, giving you a chance to track that as well if you have any. TipRanks tips the scales by having a ton of tools for investors. That includes the usual stuff like charts and analytics, along with things like stock futures, stock price alerts, earnings, dividends, and other information. It tends to lean more on analytics than news aggregation, which makes it different from something like Yahoo Finance, where news comes first and analytics comes second. That makes it good for folks looking to number crunch instead of reading the latest from the big business blogs. Like most, TipRanks has a subscription service as well. It runs for $29.95 per month or $19.95 per month on average if you let it bill you for every three years. The subscription unlocks a portfolio analysis tool to see how your picks stack up. There is also a real-time news feed along with investment ideas to give you an idea of where to invest next. TipRanks has earned its higher rating with a litany of good features. Seeking Alpha is a well-known stocks and news website that helps people make stock picks. Its main claim to fame is that is has a ton of analysis that result in recommendations for stock picks. Overall, Seeking Alpha boasts a fairly good track record overall, beating the S&P by a fairly hefty margin. If you want a company telling you how to invest your money, this is a good place to start. The app is good at other things as well. It has a portfolio tracker function where you can see how your stocks are doing along with the usual array of features like a news feed, statistics about stocks, and watchlists so you can keep track of companies. It augments that with alerts and ratings about each stock to give you an at-a-glance view of how a stock is performing. All of that comes with the free membership along with one premium-level news article per month. Seeking Alpha has two subscription tiers and one of them is rather expensive. The less expensive version costs $239 per year and grants you increased access to the app, including a social feature where you can talk about stocks with other investors along with the brand's various stock ratings and recommendations. There is a second option for $1,189 per year and that is not a typo. That tier grants even more access to analytics, stock recommendations, and a special shortlist of companies. Betterment is one of several decent apps on iOS that actually lets you invest money. The whole premise of the app is that you put money into it, and it'll invest it automatically in you. From there, you keep adding, and your investments keep growing until they're enough. Most of the features center around this premise, so you won't be using this one to check stock prices or read the news. You log in, deposit money, check your investments, and log out. There are some features worth mentioning. The app can set recurring monthly deposits so you don't have to remember to do it manually and there are various retirement accounts you can start that return various amounts of dividends every year. It isn't free, though. The subscription is $4 per month until you hit $20,000, and then it automatically switches to 0.25% of your yearly earnings. Folks who want to make it to over $100,000 can get another tier with one-to-one advice about investing the money. There are other popular apps on iOS that also do things like this. Wealthfront is very similar to Betterment and has reviews on par with Betterment, so you can go with either one. Acorns is a little more friendly to beginners as it allows you to invest little bits at a time that grow. Either way, all three apps are excellent to get started saving for retirement, and they're a little easier to grasp than some of the more traditional models. The final app on our list is TradingView with an incredible 4.9 rating on the Apple App Store. This one is similar to Delta, Investing.com, and others with the main purpose of delivering stats and information about the stock market and other investments you might be interested in. It ticks the boxes with charts, data, and news aggregation. There are also functions to track your portfolio and get alerts on stock prices. There are even calendars and other such tools to keep you informed about what's going on. However, data is TradingView's main draw. It has better charts than some desktop apps and so much data that even experienced investors will have their hands full. That includes market data from Asia, Europe, and other markets, resulting in hundreds of thousands of symbols for users to look up. The other feature that this app has that most don't is the ability to practice investing by having paper trading available. You can invest with fake money into real stocks and see how well you would've theoretically done. There are three subscription options to choose from that range from $12.95 to $49.95. Each successive tier grants more access to more charts, more data, and more features. There are also add-ons that are required to see some things, like real-time stock quotes from overseas. The price of the app can get up there pretty quickly depending on what you need but even free accounts get more features than most other apps out there.
Federal Agricultural Mortgage Corp director sells $307,040 in stockAaron Connolly was on target for Sunderland in their draw at home to Millwall on a day when Irish eyes were smiling in the Championship. Connolly blasted home from the edge of the box to give the Black Cats an early lead but they were denied in added time when Femi Azeez scored. Elsewhere, Finn Azaz bagged a brace in Middlesbrough’s 6-2 win away at Oxford, Mark McGuinness got the only goal as Luton beat Hull and Tom Cannon was on target for Stoke in their 1-1 draw with QPR. We need your consent to load this Social Media content. We use a number of different Social Media outlets to manage extra content that can set cookies on your device and collect data about your activity. Championship round-up Ten-man Sheffield United were unable to fully build on their lead at the top of the Sky Bet Championship as they were held 2-2 at Coventry. Tyrese Campbell opened the scoring before Norman Bassette scored his first Coventry goal to level. Jesurun Rak-Sayki put the Blades back in front before Anel Ahmedhodzic was sent off for grabbing Bassette by the throat and throwing him to the floor in a crazy rush of blood just before half-time. Coventry piled on the pressure in the second half as Bobby Thomas headed Coventry level with 10 minutes remaining. As a result Burnley were able to close in on them – with Leeds playing at Swansea on Sunday – thanks to a 1-0 win at Bristol City, earned by Jaidon Anthony. Sunderland, though, were denied the same when Femi Azeez levelled three minutes into stoppage time as they drew 1-1 at Millwall in a game heavily delayed by medical emergencies in the crowd. Aaron Connolly’s goal put the Black Cats ahead but they were unable to hold out. Middlesbrough smashed six goals past Oxford to signal their intent to disrupt the order at the top. Emmanuel Latte Lath scored a hat-trick, one from the spot, Finn Azaz a brace and Tommy Conway the other, with Greg Leigh and Dane Scarlett responding. We need your consent to load this Social Media content. We use a number of different Social Media outlets to manage extra content that can set cookies on your device and collect data about your activity. Norwich are without a win in seven after they drew 2-2 at West Brom. They went behind to Mason Holgate, but quickly led thanks to Emiliano Marcondes and an own goal from Torbjorn Heggem, but their lead lasted just two minutes before Josh Maja equalised. Sam Greenwood and Jerry Yates traded goals as Preston and Derby drew 1-1, while a Ben Gibson own goal bailed out QPR as they drew 1-1 with Stoke. Tom Cannon give City the lead and Zan Celar missed a penalty for rock-bottom QPR. At Hillsborough, Di’Shon Bernard’s first Championship goal for Sheffield Wednesday cancelled out Ollie Tanner’s opener as the Owls drew 1-1 with Cardiff. At the foot of the table, Luton’s Rob Edwards emerged from the clash of under-pressure managers as his side beat Tim Walter’s Hull 1-0 thanks to Mark McGuinness’ goal. Hull are now in the relegation zone.CRANFORD, N.J. , Dec. 27, 2024 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") CTOR , a specialty biopharmaceutical company focused on the development and commercialization of novel targeted oncology therapies, today reported business and financial results for the fiscal full year ended September 30, 2024 . Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIRTM (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL); Began trading on the Nasdaq exchange under the ticker symbol CTOR on August 13, 2024 , following completion of the merger of Citius Pharma's oncology subsidiary with TenX Keane to form Citius Oncology, Inc., a standalone publicly traded company; Advanced manufacturing, marketing and sales activities in preparation for commercial launch of LYMPHIR in the first half of 2025; key activities included: Manufactured initial inventory for launch and finalized supply chain agreements, Initiated recruitment of targeted field force with contract sales organization, Launched a marketing awareness campaign and engaged with all leading CTCL prescribers, Applied for a unique J-code within the Healthcare Common Procedure Coding System (HCPCS) to facilitate accurate reimbursement, Secured inclusion of LYMPHIR in the National Comprehensive Cancer Network (NCCN) guidelines, critical to clinical decision-making in oncology and hematology, influencing treatment practices and payor reimbursement in the U.S., and Initiated development of the patient support center to help patients access LYMPHIR expeditiously; Supported two investigator-initiated trials to explore LYMPHIR's potential as an immuno-oncology combination therapy being conducted at the University of Pittsburgh Medical Center and the University of Minnesota ; and, Shared interim trial results with the clinical community at the Society for Immunotherapy of Cancer Conference (SITC) of University of Pittsburgh Medical Center's Phase I trial of LYMPHIR with checkpoint inhibitor pembrolizumab. The combination of these two immunomodulatory agents showed clinical benefit in relapsed or refractory gynecological neoplasms, resulting in: 27% objective response rate and 33% clinical benefit rate with median progression free survival of 57 weeks (range: 30-96 weeks), and A manageable safety profile whereby the regimen was well-tolerated with reversible treatment emergent adverse events and no definitive immune-related adverse events greater than or equal to grade 3 documented. Financial Highlights R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 ; G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 ; Stock-based compensation expense was $7.5 million for the full year ended September 30, 2024 , compared to $2.0 million for the full year ended September 30, 2023 ; and, Net loss was $21.1 million , or ($0.31) per share for the full year ended September 30, 2024 compared to a net loss of $12.7 million , or ($0.19) per share for the full year ended September 30, 2023 . "Reflecting on 2024, Citius Oncology has achieved pivotal milestones that underscore our commitment to advancing cancer therapeutics," stated Leonard Mazur , Chairman and CEO of Citius Oncology. "The FDA's approval of LYMPHIR for the treatment of cutaneous T-cell lymphoma marks a significant advancement in providing new options for patients battling this challenging disease. It is the only targeted systemic therapy approved for CTCL patients since 2018 and the only therapy with a mechanism of action that targets the IL-2 receptor. Additionally, the successful merger forming Citius Oncology, now trading on Nasdaq under the ticker CTOR, strengthens our position in the oncology sector. We expect it to facilitate greater access to capital to fund LYMPHIR's launch and the Company's future growth. With a Phase I investigator-initiated clinical trial combining LYMPHIR with pembrolizumab demonstrating promising preliminary results, indicating potential for enhanced treatment efficacy in recurrent solid tumors, and preliminary results expected from a second investigator trial with CAR-T therapies in 2025, we remain excited about the potential of LYMPHIR as a combination immunotherapy." "These accomplishments reflect the dedication of our team and the trust of our investors. As we look ahead, we remain steadfast in our mission to develop innovative therapies that improve the lives of cancer patients worldwide," added Mazur. FULL YEAR 2024 FINANCIAL RESULTS: Research and Development (R&D) Expenses R&D expenses were $4.9 million for the full year ended September 30, 2024 , compared to $4.2 million for the full year ended September 30, 2023 . The increase reflects development activities completed for the resubmission of the Biologics License Application of LYMPHIR in January 2024 , which were associated with the complete response letter remediation. General and Administrative (G&A) Expenses G&A expenses were $8.1 million for the full year ended September 30, 2024 , compared to $5.9 million for the full year ended September 30, 2023 . The increase was primarily due to costs associated with pre-commercial and commercial launch activities of LYMPHIR including market research, marketing, distribution and drug product reimbursement from health plans and payers. Stock-based Compensation Expense For the full year ended September 30, 2024 , stock-based compensation expense was $7.5 million as compared to $2.0 million for the prior year. The primary reason for the $5.5 million increase was due to the amounts being realized over 12 months in the year ended September 30, 2024 , as compared to three months post-plan adoption in the year ended September 30, 2023 . Net loss Net loss was $21.1 million , or ($0.31) per share for the year ended September 30, 2024 , compared to a net loss of $12.7 million , or ($0.19) per share for the year ended September 30, 2023 . The $8.5 million increase in net loss was primarily due to the increase in our operating expenses. About Citius Oncology, Inc. Citius Oncology specialty is a biopharmaceutical company focused on developing and commercializing novel targeted oncology therapies. In August 2024 , its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million , is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. For more information, please visit www.citiusonc.com Forward-Looking Statements This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius Oncology. You can identify these statements by the fact that they use words such as "will," "anticipate," "estimate," "expect," "plan," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated, and, unless noted otherwise, that apply to Citius Oncology are: our ability to raise additional money to fund our operations for at least the next 12 months as a going concern; our ability to commercialize LYMPHIR and any of our other product candidates that may be approved by the FDA; the estimated markets for our product candidates and the acceptance thereof by any market; the ability of our product candidates to impact the quality of life of our target patient populations; our dependence on third-party suppliers; our ability to procure cGMP commercial-scale supply; risks related to research using our assets but conducted by third parties; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; market and other conditions; risks related to our growth strategy; patent and intellectual property matters; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; government regulation; competition; as well as other risks described in our Securities and Exchange Commission ("SEC") filings. These risks have been and may be further impacted by any future public health risks. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our SEC filings which are available on the SEC's website at www.sec.gov , including in Citius Oncology's Annual Report on Form 10-K for the year ended September 30, 2024 , filed with the SEC on December 27, 2024 , as updated by our subsequent filings with the SEC. These forward-looking statements speak only as of the date hereof, and we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law. Investor Contact: Ilanit Allen ir@citiuspharma.com 908-967-6677 x113 Media Contact: STiR-communications Greg Salsburg Greg@STiR-communications.com -- Financial Tables Follow – CITIUS ONCOLOGY, INC. CONSOLIDATED BALANCE SHEETS SEPTEMBER 30, 2024 AND 2023 2024 2023 Current Assets: Cash and cash equivalents $ 112 $ — Inventory 8,268,766 — Prepaid expenses 2,700,000 7,734,895 Total Current Assets 10,968,878 7,734,895 Other Assets: In-process research and development 73,400,000 40,000,000 Total Other Assets 73,400,000 40,000,000 Total Assets $ 84,368,878 $ 47,734,895 LIABILITIES AND STOCKHOLDERS' EQUITY Current Liabilities: Accounts payable $ 3,711,622 $ 1,289,045 License payable 28,400,000 — Accrued expenses — 259,071 Due to related party 588,806 19,499,119 Total Current Liabilities 32,700,429 21,047,235 Deferred tax liability 1,728,000 1,152,000 Note payable to related party 3,800,111 — Total Liabilities 38,228,540 22,199,235 Stockholders' Equity: Preferred stock - $0.0001 par value; 10,000,000 shares authorized: no shares issued and outstanding — — Common stock - $0.0001 par value; 100,000,000; 71,552,402 and 67,500,000 shares issued and outstanding at September 30, 2024 and 2023, respectively 7,155 6,750 Additional paid-in capital 85,411,771 43,658,750 Accumulated deficit (39,278,587) (18,129,840) Total Stockholders' Equity 46,140,339 25,535,660 Total Liabilities and Stockholders' Equity $ 84,368,878 $ 47,734,895 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF OPERATIONS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Revenues $ — $ — Operating Expenses: Research and development 4,925,001 4,240,451 General and administrative 8,148,929 5,915,290 Stock-based compensation – general and administrative 7,498,817 1,965,500 Total Operating Expenses 20,572,747 12,121,241 Loss before Income Taxes (20,572,747) (12,121,241) Income tax expense 576,000 576,000 Net Loss $ (21,148,747) $ (12,697,241) Net Loss Per Share – Basic and Diluted $ (0.31) $ (0.19) Weighted Average Common Shares Outstanding – Basic and Diluted 68,053,607 67,500,000 CITIUS ONCOLOGY, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE YEARS ENDED SEPTEMBER 30, 2024 AND 2023 2024 2023 Cash Flows From Operating Activities: Net loss $ (21,148,747) $ (12,697,241) Adjustments to reconcile net loss to net cash provided by operating activities: Stock-based compensation expense 7,498,817 1,965,500 Deferred income tax expense 576,000 576,000 Changes in operating assets and liabilities: Inventory (2,133,871) - Prepaid expenses (1,100,000) (5,044,713) Accounts payable 2,422,577 1,196,734 Accrued expenses (259,071) (801,754) Due to related party 14,270,648 14,805,474 Net Cash Provided By Operating Activities 126,353 - Cash Flows From Investing Activities: License payment (5,000,000) - Net Cash Used In Investing Activities (5,000,000) - Cash Flows From Financing Activities: Cash contributed by parent 3,827,944 - Merger, net (2,754,296) - Proceeds from issuance of note payable to related party 3,800,111 - Net Cash Provided By Financing Activities 4,873,759 - Net Change in Cash and Cash Equivalents 112 - Cash and Cash Equivalents – Beginning of Year - - Cash and Cash Equivalents – End of Year $ 112 $ - Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $ - Capital Contribution of due to related party by parent $ 33,180,961 $ - Prepaid Manufacturing transferred to Inventory $ 6,134,895 $ - View original content to download multimedia: https://www.prnewswire.com/news-releases/citius-oncology-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339671.html SOURCE Citius Oncology, Inc. © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
The United States has revealed shocking information about the growing military ties between North Korea and Russia. According to the head of the U.S. Pacific Command, Russia is going to give North Korea advanced fighter jets in exchange for the thousands of soldiers Pyongyang has reportedly sent to support Moscow’s ongoing war in Ukraine. This military cooperation is a significant shift in the dynamics of international alliances and raises concerns about its potential consequences. North Korean Troops Sent To Russia’s War Front US Indo-Pacific Command Admiral Samuel Paparo confirmed that North Korean forces have been deployed on Russian front lines in the region of Kursk where Ukrainian forces have been trying to mount a counter offensive against Russian troops since the month of August. However, while Paparo acknowledged that these North Korean soldiers are positioned in active combat zones, he clarified that they have not yet engaged in fighting. This statement contradicts the claims of Ukrainian President Volodymyr Zelensky, who previously suggested that the North Korean forces had already participated in the conflict. North Korean soldiers in the conflict zone of Ukraine: A deeper commitment by the two countries to supporting Russia’s war effort and a growing military alliance. Fighter Jets For North Korea Reports indicate that it will provide North Korea’s MiG-29 and Su-27 fighter jets in exchange for the involvement of North Korean troops in its forces. The above-mentioned Soviet-era jet was introduced over four decades ago, and its influence on North Korea’s airpower is expected to make a huge difference. MiG-29 and Su-27 are not actually considered modern platforms, yet they are still formidable pieces of equipment that will probably give Pyongyang a strategic uplift in its air force ability. Admiral Paparo said that even though they are old, these aircraft are still very potent weapons in the arsenal of North Korea. Traditionally, North Korea has acquired its combat aircraft from the Soviet Union and later from China. South Korea, on the other hand, has more advanced aircraft, including U.S.-made F-15s, F-16s, F-35 stealth fighters, and the indigenous KAI T-50. Escalating military cooperation between Russia and North Korea has sent alarm bells around the world. The United States and its allies have grave concerns about the transfer of advanced military technology resulting from these expanded ties for the development of North Korea’s ballistic missile and nuclear weapons programs. The United Nations has been sanctioning Pyongyang for years due to its weapons programs, and the presence of Russia being able to help circumvent that could be quite problematic. Recent reports indicate that the two countries have had mutual military exchanges in the past few months. The defense chief of South Korea recently confirmed that Russia had sent air defense missiles to North Korea, likely in return for Pyongyang’s contribution of fresh troops to the Russian cause. Seoul has also accused North Korea of sending large quantities of munitions to replenish Russia’s dwindling stockpiles, further deepening the military collaboration between the two countries. It appears that Ukraine , in its military equipment needs, would still have to rely on aging fighter jets such as the F-16 fighter jets supplied by European allies. Ukraine has been ordered more F-16 next year, with France confirming that it would send some Mirage 2000 fighters, which have been operational for over 40 years, just like the MiG-29 and the Su-27. However, the dynamics of the current war in Ukraine are complicated because both sides are relying on outdated military technology, plus the rapidly shifting alignments of global military powers. Growing North Korea-Russia Alliance The growing partnership between Russia and North Korea has raised regional and international concerns. US Defense Secretary Lloyd Austin labeled the deployment of North Korean soldiers to the front lines of Russia a “dangerous and destabilizing escalation.” This is a point that reflects increased tensions and broader implications. Earlier this year, Russian President Vladimir Putin and North Korean leader Kim Jong Un signed a historic military cooperation agreement. Both nations have tried to tone down the importance of the pact, saying it does not threaten countries that are not engaging in hostile actions. But the growing military contacts between the two nations and North Korean troops deployment together with the transfer of fighter jets have raised the alarms for further destabilization within the region. ALSO READ | Nancy Mace Faces Backlash As Old Drinking Game Video Surfaces Amid Transgender Debate
Mechanical, Electrical, and Plumbing (MEP) Software Market to Reach USD 8.4 Billion by 2031 | TMR
How to get started with Bluesky
– Hip-hop mogul 50 Cent seized an opportunity to mock JAY-Z amid a lawsuit alleging serious misconduct involving both Shawn “JAY-Z” Carter and Sean “Diddy” Combs. The lawsuit, filed by attorney Tony Buzbee, accuses the two rap icons of sexually assaulting a 13-year-old girl after the 2000 Video Music Awards, claims both men have vehemently denied. The lawsuit, which originally named Diddy as the sole defendant when filed in October, was amended on December 8 to include JAY-Z. It alleges the two men “took turns assaulting the minor” while an unnamed female celebrity reportedly observed. In a statement, JAY-Z called the allegations “heinous” and accused the attorney of engaging in “theatrics” rather than pursuing justice. “Whoever would commit such a crime against a minor should be locked away. Would you not agree? These alleged victims deserve real justice if that were the case,” JAY-Z said. He vowed to defend his name, adding, “You have made a terrible error in judgment thinking that all ‘celebrities’ are the same. I’m not from your world. I’m a young man who made it out of the projects of Brooklyn... We have very strict codes and honor. We protect children.” 50 Cent, known for his provocative online persona, reacted with a thinly veiled jab, referencing JAY-Z’s NFL partnership and role in the Super Bowl. “Ok I don’t know what’s going on, but are we gonna still have the Super Bowl?” he quipped on Instagram. “I’m just asking for a friend!” Although he didn’t explicitly name JAY-Z or Diddy, 50 Cent’s comment added fuel to the social media frenzy surrounding the lawsuit. The allegations have sparked widespread shock and debate online, with fans and critics alike expressing disbelief and demanding accountability. Both JAY-Z and Diddy continue to deny any wrongdoing, with their legal teams vowing to fight the claims in court. As the case unfolds, the lawsuit highlights the intersection of fame, power, and allegations of abuse, raising serious questions about accountability in the entertainment industry. Source:Hugel and Medica join forces to boost botulinum toxin sales in Middle East, North Africa